Entrada Therapeutics, Inc.
Clinical trials sponsored by Entrada Therapeutics, Inc., explained in plain language.
-
New hope for duchenne: targeted therapy ENTR-601-45 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called ENTR-601-45 in 24 people with Duchenne muscular dystrophy who have a specific genetic mutation (exon 45 skipping). The goal is to check the drug's safety, find the right dose, and see if it can help muscles work better. Participants re…
Phase: PHASE1, PHASE2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 07:22 UTC
-
New drug hopes to slow duchenne in boys with specific gene mutation
Disease control Recruiting nowThis study tests an investigational drug called ENTR-601-44 in 24 boys and young men with Duchenne muscular dystrophy (DMD) who have a specific genetic change (exon 44 skipping). The goal is to see if the drug is safe, tolerable, and can help improve muscle function compared to a…
Phase: PHASE1, PHASE2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 14:01 UTC